Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma

Journal of Clinical Oncology, 05/02/2012

Erlotinib and erlotinib plus chemotherapy have similar efficacy in clinically selected populations of patients with advanced non–small–cell lung cancer (NSCLC). EGFR mutations identify patients most likely to benefit.

Print Article Summary Cat 2 CME Report